Fig 5.
ApoBSecNEP reduces Aβ in the CNS of APP tg mice.
Sections from APP tg mice that had received peripheral injections with the lentiviral vectors were homogenized, fractioned and examined for levels of APP and Aβ by western blot. (A) Representative immunoblot probed with the 82E1 monoclonal antibody displaying the reduction in the levels of Aβ in APP tg mice treated with LV-ApoBSecNEP. (B–C) Analysis of immunoblot for levels of Aβ monomers and full length APP. (D–G) Low magnification view of sections from APP tg mice treated with LV-control, LV-NEP, LV-SecNEP or LV-ApoBSecNEP respectively and immunolabeled with a monoclonal antibody against Aβ (82E1) imaged with the laser scanning microscope. (H) Computer aided image analysis of the % area of the neuropil occupied by Aβ immunoreactive deposits. (I–L) Higher magnification view of the Aβ immunoreactive plaques in APP tg mice treated with the various lentiviruses. (M–P) Representative images of the patterns of intraneuronal APP/Aβ immunostaining in the frontal cortex from APP tg mice treated with LV-Control, LV-NEP, LV-SecNEP or LV-ApoBSecNEP respectively immunolabeled with a monoclonal antibody against Aβ (82E1) imaged with the laser scanning microscope. (Q) Image analysis of levels of intracellular APP/Aβ immunostaining. Scale bar = 15 µm for I-L and 10 µm for M-P. * - indicates statistically significant difference by 1-way ANOVA with poshoc Dunnet’s when compared to LV-Control treated animals (p < 0.05). n = 8 mice per group.